
Obesity, a multifaceted health concern affecting millions globally, demands innovative solutions beyond conventional diet and exercise regimes. Amidst the array of medications and therapies, GLP-1 agonists, such as Ozempic, Wegovy and Mounjaro, emerge as a beacon of hope,